Profile data is unavailable for this security.
About the company
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
- Revenue in SEK (TTM)41.77m
- Net income in SEK-24.91m
- Incorporated2010
- Employees16.00
- LocationSenzaGen ABMedicon VillageBuilding 401, Scheelevagen 2LUND 223 63SwedenSWE
- Phone+46 462756200
- Websitehttps://senzagen.com/
More ▼
Mergers & acquisitions
| Acquired company | SENZA:STO since announced | Transaction value |
|---|---|---|
| Toxhub Srl | -14.40% | 306.00k |
Data delayed at least 15 minutes, as of May 30 2023 09:59 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moberg Pharma AB (publ) | 207.00k | -16.30m | 209.28m | -- | -- | 0.3854 | -- | 1,011.03 | -1.88 | -1.88 | 0.0231 | 53.84 | 0.0004 | -- | 0.0348 | -- | -3.25 | -- | -3.36 | -- | 100.00 | -- | -7,873.43 | -- | -- | -- | 0.0091 | -- | -- | -78.39 | 2.40 | -- | -- | -- |
| Active Biotech AB publ | 0.00 | -58.40m | 212.17m | 11.00 | -- | 6.15 | -- | -- | -0.2475 | -0.2475 | 0.00 | 0.1302 | 0.00 | -- | -- | -- | -108.34 | -33.26 | -136.13 | -77.77 | -- | -- | -- | -600.78 | -- | -144.75 | 0.1131 | -- | -- | -- | -17.21 | -- | -- | -- |
| ExpreS2ion Biotech Holding AB | 6.66m | -131.08m | 214.48m | 28.00 | -- | 2.06 | -- | 32.19 | -3.36 | -3.36 | 0.172 | 2.11 | 0.0548 | -- | 5.19 | 222,066.70 | -107.81 | -58.88 | -120.43 | -69.62 | -208.69 | 25.33 | -1,967.53 | -394.75 | -- | -- | 0.0547 | -- | -55.21 | -8.89 | -170.02 | -- | 13.21 | -- |
| Arctic Bioscience AS | 33.34m | -33.10m | 227.09m | -- | -- | 0.7806 | -- | 6.81 | -1.40 | -1.40 | 1.41 | 11.79 | 0.1024 | 0.7072 | 3.24 | -- | -10.17 | -- | -11.20 | -- | 33.98 | -- | -99.28 | -- | 4.03 | -- | 0.00 | -- | 59.29 | -- | 20.09 | -- | -- | -- |
| Abliva AB | 31.00k | -79.33m | 228.69m | 6.00 | -- | 1.53 | -- | 7,377.06 | -0.1162 | -0.1162 | 0.00004 | 0.1411 | 0.0003 | -- | 0.001 | 5,166.67 | -72.67 | -73.09 | -81.76 | -85.88 | -- | -- | -255,896.80 | -78,072.63 | -- | -37.56 | 0.00 | -- | -79.47 | 2.80 | 30.96 | -- | -26.59 | -- |
| Mendus AB (publ) | 0.00 | -141.37m | 232.50m | 33.00 | -- | 0.4812 | -- | -- | -0.7128 | -0.7128 | 0.00 | 2.42 | 0.00 | -- | -- | 0.00 | -21.18 | -21.38 | -22.98 | -23.23 | -- | -- | -- | -28,264.99 | -- | -27.86 | 0.1429 | -- | -- | -- | -4.03 | -- | -- | -- |
| Kancera AB | 0.00 | -57.98m | 232.70m | 7.00 | -- | 2.54 | -- | -- | -1.01 | -1.01 | 0.00 | 1.12 | 0.00 | -- | -- | -- | -50.93 | -56.25 | -57.99 | -68.43 | -- | 94.68 | -- | -6,023.47 | -- | -78.97 | 0.00 | -- | -- | -- | -14.88 | -- | -- | -- |
| Lifecare AS | 21.54m | -17.00m | 244.26m | -- | -- | 4.54 | -- | 11.34 | -0.148 | -0.148 | 0.1878 | 0.4688 | 0.4332 | -- | 30.31 | -- | -34.20 | -41.60 | -39.09 | -47.04 | -- | -- | -78.96 | -147.96 | -- | -- | 0.00 | -- | 1,284.20 | 109.30 | -10.08 | -- | -- | -- |
| Opticept Technologies AB | 11.47m | -106.25m | 263.04m | -- | -- | 0.6942 | -- | 22.94 | -5.26 | -5.26 | 0.5134 | 12.69 | 0.0273 | 0.5937 | 2.14 | -- | -25.20 | -44.86 | -27.03 | -49.01 | -6.06 | 42.23 | -922.44 | -863.20 | 1.45 | -11.15 | 0.0593 | -- | 136.46 | 122.77 | -112.89 | -- | 35.79 | -- |
| SenzaGen AB | 41.77m | -24.91m | 268.32m | 16.00 | -- | 3.01 | -- | 6.42 | -1.03 | -1.03 | 1.73 | 3.71 | 0.3292 | 4.24 | 4.56 | -- | -19.63 | -25.18 | -24.68 | -27.95 | 65.44 | 78.89 | -59.64 | -214.33 | 1.86 | -- | 0.0133 | -- | 170.85 | 105.03 | 20.53 | -- | -29.85 | -- |
| Initiator Pharma A/S | 0.00 | -50.60m | 283.32m | -- | -- | 7.38 | -- | -- | -1.00 | -1.00 | 0.00 | 0.7345 | 0.00 | -- | -- | -- | -84.78 | -68.41 | -92.84 | -75.18 | -- | -- | -- | -- | -- | -- | 0.3392 | -- | -- | -- | -82.56 | -- | -- | -- |
| Biovica International AB | 3.88m | -91.85m | 289.32m | 33.00 | -- | 1.92 | -- | 74.59 | -2.81 | -2.81 | 0.1169 | 3.82 | 0.0216 | -1.67 | 8.55 | 155,160.00 | -51.17 | -30.85 | -55.61 | -33.47 | 152.10 | 332.81 | -2,367.83 | -1,470.09 | 8.35 | -543.41 | 0.0592 | -- | -1.54 | 26.47 | -51.97 | -- | -- | -- |
| Intellego Technologies AB | 57.78m | -9.96m | 316.24m | -- | -- | 15.09 | -- | 5.47 | -0.4567 | -0.4567 | 2.79 | 0.9478 | 0.5703 | 4.30 | 9.42 | -- | -9.83 | -- | -19.07 | -- | 53.79 | -- | -17.24 | -- | 0.6917 | -3.08 | 0.5113 | -- | 531.64 | -- | -151.46 | -- | -- | -- |
| AlzeCure Pharma AB | 0.00 | -53.14m | 317.89m | 12.00 | -- | 6.24 | -- | -- | -1.01 | -1.01 | 0.00 | 0.821 | 0.00 | -- | -- | 0.00 | -79.59 | -44.86 | -94.34 | -47.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.70 | -- | -- | -- |
| Exact Therapeutics AS | 0.00 | -39.02m | 329.80m | 8.00 | -- | 5.21 | -- | -- | -1.34 | -1.34 | 0.00 | 2.17 | -- | -- | -- | -- | -- | -28.38 | -- | -32.26 | -- | -- | -- | -- | -- | -- | 0.0252 | -- | -- | -- | -- | -- | -- | -- |
| Corline Biomedical AB | 27.88m | 4.20m | 330.96m | 8.00 | 78.80 | 3.46 | 77.56 | 11.87 | 0.1954 | 0.1954 | 1.30 | 4.45 | 0.2778 | -- | 9.88 | -- | 4.18 | -7.76 | 4.49 | -8.58 | 99.92 | 151.14 | 15.07 | -76.39 | -- | -- | 0.00 | -- | 233.47 | 105.79 | 133.65 | -- | 12.38 | -- |
Data as of May 30 2023. Currency figures normalised to SenzaGen AB's reporting currency: Swedish Krona SEK
0.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2022 | 190.50k | 0.79% |
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
